Business Profile & Competitive Position
The Clorox Company operates in the Consumer Defensive sector under the Household & Personal Products industry. It is a multinational manufacturer and marketer of both consumer and professional products, running roughly 9,200 employees across about 25 countries and selling into approximately 95 markets. Its brand portfolio includes household names such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional division sells under the Purell, CloroxPro, and Clorox Healthcare brands.
Margin and return figures tell a mixed story about competitive moat. The company’s net margin of 8.7% suggests that its brand portfolio still commands some pricing power, though it is not an unusually wide margin for a packaged-goods peer. The reported return on equity of -1,893.5% is far more extreme and, given the positive net margin, likely reflects a very small or negative book-equity base rather than an operational meltdown. A beta of 0.57 lines up with the defensive profile: demand for bleach, trash bags, cat litter, and water filters generally holds steady through economic cycles.
At the same time, customer concentration is a structural feature of the business. In fiscal 2026, Walmart accounted for 26% of consolidated net sales, and the five largest customers together represented about half of consolidated net sales. That concentration gives Clorox scale, but it also means that续约 terms, shelf-space resets, and pricing negotiations with a handful of retailers can materially affect performance.
Financial Posture
Clorox’s current market capitalization stands at $10.6 billion, with the stock trading at a price-to-earnings ratio of 18.3. In a low-beta Consumer Defensive name, that multiple sits in a moderate zone rather than an obviously stretched one, though it still prices in a return to steadier earnings growth after a weak fiscal 2026.
Profitability is observable in the net margin of 8.7%, but the -1,893.5% ROE is effectively unusable as a ordinary profitability signal because of the balance-sheet mechanics behind it. Investors focused on shareholder returns should therefore look beyond headline ROE and instead examine how operating cash flow, interest coverage, and pension or leverage obligations interact with the thin equity base.
The beta of 0.57 indicates the stock historically has moved a little over half as much as the broad market, which is consistent with a defensive staples business. Near term, the share price is around $88, sitting just below the 50-day exponential moving average of $88.47, while the RSI at 53.8 is close to neutral territory.
Strategic Priorities & Outlook
Clorox’s most recent 10-K lays out a clear operational agenda. The company is executing its IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.
Completing and optimizing a new enterprise resource planning (ERP) system is a central near-term goal. Clorox expects the broader digital transformation to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. That said, fiscal 2026 already showed the friction that can come with large technology transitions: organic sales and earnings declined, and diluted EPS fell 26%, partly because ERP timing had pulled some sales into fiscal 2025.
On the portfolio side, the company completed its acquisition of GOJO Industries in April 2026, expanding its health and hygiene footprint and strengthening its business-to-business presence. Clorox also wants to advance health and hygiene expansion and optimize the portfolio, including growing professional and institutional markets. A related structural change was the expiration of the Glad bags and wraps venture with Procter & Gamble on January 31, 2026; Clorox purchased P&G’s 20% interest, and Glad retained core intellectual-property licenses on a royalty-free basis.
Macro & Geopolitical Exposure
As a Household & Personal Products company, Clorox is exposed to commodity and input-cost volatility. Plastics, resins, chemicals, paper, and agricultural oils are major cost drivers across cleaning, trash-bag, pet-care, and food categories. Freight, warehousing, and logistics costs can also swing results, especially when retailer replenishment patterns shift.
Regulatory oversight matters here too. Cleaning products face Environmental Protection Agency (EPA) registration and labeling requirements, while personal-care and health-oriented products can fall under Food and Drug Administration (FDA) scrutiny. Health and hygiene claims require careful substantiation, and any tightening of chemical regulations can force formulation changes.
Because Clorox sells in roughly 95 markets, currency translation is another factor: a stronger U.S. dollar tends to reduce the dollar value of overseas revenue and profits, while a weaker dollar has the opposite effect. Trade policy, including tariffs on imported raw materials or finished goods, could also affect margins. Finally, the sector is vulnerable to private-label competition and retailer promotional intensity, both of which can pressure branded pricing power during soft consumer-spending periods.
Recent Developments
A cluster of headlines in late October and early November 2026 has centered on Clorox’s earnings setup and dividend sustainability.
- On 2026-10-29, Seeking Alpha published “Clorox: An Easy Quarter Ahead, But A Harder Test For The Dividend,” flagging that near-term results may look manageable while dividend coverage remains the larger debate.
- On 2026-10-30, Seeking Alpha ran “Clorox: Valuation Bleached Clean,” and Zacks followed with “Clorox's Q1 Earnings Coming Up: Key Insights for Investors,” both focusing on valuation ahead of the next report.
- On 2026-11-01, 247wallst.com asked “Clorox vs. Procter & Gamble: Which Dividend Is Safer for Retirement?”—a reminder that income durability is a key part of how investors evaluate the stock.
The common thread across these pieces is not the quarter’s headline number in isolation, but how margins, leverage, and cash generation fit together over time. After the weak fiscal 2026, the market appears to be using the upcoming report to assess whether the ERP rollout, GOJO integration, and cost actions are starting to produce a more stable earnings path.
Earnings Behavior & Post-Earnings Drift
Clorox’s earnings track record over the last eight quarters shows a 75% beat rate, with the company topping estimates in six of those eight reports. The average earnings surprise across that period is 9.6%, while the average five-day price move after the report is +1.67%, classified as an upward post-earnings drift.
The most recent results illustrate how noisy that drift can be:
- 2026-08-03: Actual EPS of $1.66 beat the $1.64 estimate by 1.2%. The stock rose 6.52% the next session and 9.61% over the following five trading days.
- 2026-04-30: Actual EPS of $1.64 beat the $1.55 estimate by 5.8%, yet the stock fell 9.67% the next day and 4.49% over the next five days.
- 2026-02-03: Actual EPS of $1.39 missed the $1.43 estimate by 2.8%, but the stock still gained 2.43% the next day and 5.63% over the following five days.
- 2025-11-03: Actual EPS of $0.85 beat the $0.818 estimate by 3.9%, with the stock rising 1.17% the next day before slipping 4.08% over the next five days.
The next scheduled report is 2026-11-02 after the close, with the current consensus EPS estimate at $1.07. While the historical beat rate is solid, the wide one-day and five-day moves show that meeting or beating the estimate does not guarantee a positive price reaction. The market’s real expectation often includes commentary on margins, ERP progress, GOJO integration, and dividend coverage, all of which can override a simple beat-or-miss headline.
For a deeper dive into how institutional analysts are interpreting these signals, it is worth reviewing the full institutional verdict on Clorox, which summarizes the latest rating changes, estimate revisions, and qualitative factors behind the numbers.
Frequently Asked Questions
Why is Clorox’s ROE so negative?
With a positive net margin of 8.7%, the reported ROE of -1,893.5% is almost certainly a balance-sheet artifact rather than evidence of massive operating losses. A very small or negative shareholders’ equity base can produce an extreme ROE figure when net income is divided by that denominator. Investors should pair this metric with cash-flow and leverage analysis rather than taking it at face value.
What should I expect from Clorox’s next earnings report?
Clorox is scheduled to report on 2026-11-02 after the close, with a current consensus EPS estimate of $1.07. The company has beaten estimates in six of the last eight quarters, with an average surprise of 9.6%. However, past post-earnings price moves have been volatile, so forward guidance and updates on ERP implementation, GOJO integration, and margin recovery are likely to matter as much as the EPS number itself.
What are Clorox’s main strategic priorities?
Clorox is executing its IGNITE strategy, which focuses on long-term profitable growth, consumer-experience innovation, digital transformation, and portfolio evolution. Near-term priorities include completing the new ERP system, integrating the GOJO acquisition completed in April 2026, and expanding health and hygiene in professional and institutional markets. Customer concentration remains a structural factor, with Walmart alone accounting for 26% of fiscal 2026 net sales.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-03 | $1.66 | $1.64 | +1.2% | +6.52% | +9.61% |
| 2026-04-30 | $1.64 | $1.55 | +5.8% | -9.67% | -4.49% |
| 2026-02-03 | $1.39 | $1.43 | -2.8% | +2.43% | +5.63% |
| 2025-11-03 | $0.85 | $0.818 | +3.9% | +1.17% | -4.08% |
| 2025-07-31 | $2.87 | $2.2 | +30.5% | - | - |
| 2025-05-05 | $1.45 | $1.55 | -6.5% | - | - |
Previous CLX editions
Get the institutional verdict on CLX
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CLX verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.